Investigational drug for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing an investigational drug (SYS6090) for advanced liver cancer (hepatocellular carcinoma). It aims to see if the drug is safe and effective for people who have not had previous systemic treatment. If you qualify, you may get access to a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that is at an advanced stage or cannot be treated with local therapies.
- You must not have had any prior systemic treatment (like chemotherapy, targeted therapy, or immunotherapy) for your liver cancer.
- Your liver function must be reasonably good (Child-Pugh score less than 7) and you must not have had a history of hepatic encephalopathy (confusion caused by liver problems).
- You must be well enough to carry out daily activities (ECOG performance status of 0 or 1).
- You must have at least one measurable tumor (a tumor that can be seen on scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a new combination of immunotherapy drugs (JS207 and JS007) against the current standard treatment (toripalimab plus bevacizumab) for advanced liver cancer that hasn't been treated before. The goal is to see if the new combo works better and shrinks tumors or delays growth.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.